China Oncology ›› 2023, Vol. 33 ›› Issue (3): 218-227.doi: 10.19401/j.cnki.1007-3639.2023.03.004
• Specialists' Commentary • Previous Articles Next Articles
Received:
2023-01-18
Revised:
2023-03-02
Online:
2023-03-30
Published:
2023-04-17
Contact:
ZHOU Caicun
CLC Number:
SU Chunxia, ZHOU Caicun. Important clinical research progress in lung cancer in 2022[J]. China Oncology, 2023, 33(3): 218-227.
[1] | WAKELEE H, ALTORKI N, FELIP E, et al. PL03.09 IMpower010: overall survival interim analysis of a phase Ⅲ study of atezolizumab vs best supportive care in resected NSCLC[J]. J Thorac Oncol, 2022, 17(9): S2. |
[2] |
O’BRIEN M, PAZ-ARES L, MARREAUD S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage ⅠB-ⅢA non-small cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial[J]. Lancet Oncol, 2022, 23(10): 1274-1286.
doi: 10.1016/S1470-2045(22)00518-6 |
[3] |
PAZ-ARES L, O’BRIEN M E R, MAUER M, et al. Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: randomized, triple-blind, phase Ⅲ EORTC-1416-LCG/ETOP 8-15-PEARLS/KEYNOTE-091 study[J]. Ann Oncol, 2022, 33(4): 451-453.
doi: 10.1016/j.annonc.2022.02.224 |
[4] | PASSARO A. Invited Discussant 1529MO, 930MO and 933MO[EB/OL]. (2022-09-12)[2023-02-02]. https://oncologypro.esmo.org/meeting-resources/esmo-congress/invited-discussant-1529mo-930mo-and-933mo. |
[5] | PROVENCIO M, SERNA R, NADAL E, et al. PL03.12 progression free survival and overall survival in NADIM Ⅱ study[J]. J Thorac Oncol, 2022, 17(9): S2-S3. |
[6] | TSUBOI M, WU Y L, GROHE C, et al. Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage ⅠB-ⅢA non-small cell lung cancer (NSCLC): updated results from ADAURA[J]. Ann Oncol, 2022, 33: S1413-S1414. |
[7] |
YUE D S, XU S D, WANG Q, et al. Updated overall survival and exploratory analysis from randomized, phase Ⅱ EVAN study of erlotinib versus vinorelbine plus cisplatin adjuvant therapy in stage ⅢA epidermal growth factor receptor + non-small cell lung cancer[J]. J Clin Oncol, 2022, 40(34): 3912-3917.
doi: 10.1200/JCO.22.00428 |
[8] | ZHONG W Z, CHEN K N, CHEN C, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage ⅢA-N2 EGFR-mutant non-small cell lung cancer (EMERGING-CTONG 1103): a randomized phase Ⅱ study[J]. J Clin Oncol, 2019, 37(25): 2235-2245. |
[9] | LYU C, FANG W, JIAO W, et al. Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage Ⅱ-ⅢB lung adenocarcinoma (NEOS): updated results[J]. Ann Oncol, 2022, 33: S71-S72. |
[10] |
TSUBOI M, WEDER W, ESCRIU C, et al. Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small cell lung cancer: NeoADAURA[J]. Future Oncol, 2021, 17(31): 4045-4055.
doi: 10.2217/fon-2021-0549 |
[11] |
FORDE P M, SPICER J, LU S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer[J]. N Engl J Med, 2022, 386(21): 1973-1985.
doi: 10.1056/NEJMoa2202170 |
[12] | SHI Y K, CHEN G, WANG X, et al. Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: a randomized, double-blind, multi-center, phase Ⅲ study (FURLONG)[J]. Ann Oncol, 2022, 33: S27. |
[13] |
YUANKAI SHI, MD, et al. Central nervous system efficacy of furmonertinib (AST2818) versus gefitinib as first-line treatment for EGFR-mutated NSCLC: results from the FURLONG study[J]. J Thorac Oncol, 2022, 17(11): 1297-1305.
doi: 10.1016/j.jtho.2022.07.1143 |
[14] | GOLDMAN J, HUANG H K T, CUMMINGS A, et al. MA07.05 phase 1b/2 study of combined HER inhibition in refractory EGFR-mutated metastatic non-small cell lung cancer (NSCLC)[J]. J Thorac Oncol, 2022, 17(9): S68-S69. |
[15] |
ALEXANDRA YU H, TAN D S W, SMIT E F, et al. Phase (Ph) 1/2a study of CLN-081 in patients (pts) with NSCLC with EGFR exon 20 insertion mutations (ins20)[J]. J Clin Oncol, 2022, 40(16_suppl): 9007.
doi: 10.1200/JCO.2022.40.16_suppl.9007 |
[16] | 16 ZHOU C C, RAMALINGAM S S, KIM T M, et al. Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial[J]. JAMA Oncol, 2021, 7(12): e214761. |
[17] | WANG M, YANG J C H, MITCHELL P, et al. Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: preliminary analysis of WU-KONG6, the first pivotal study[J]. Ann Oncol, 2022, 33: S1003-S1004. |
[18] | ZHOU Q, LI J, WANG J, et al. EP08.02-063 SANOVO: a phase 3 study of savolitinib or placebo in combination with osimertinib in patients with EGFR-mutant and MET overexpressed NSCLC[J]. J Thorac Oncol, 2022, 17(9): S429. |
[19] |
SWAIN S M, SHASTRY M, HAMILTON E. Targeting HER2-positive breast cancer: advances and future directions[J]. Nat Rev Drug Discov, 2023, 22(2): 101-126.
doi: 10.1038/s41573-022-00579-0 |
[20] |
GOLDMAN J W, HORINOUCHI H, CHO B C, et al. Phase 1/1b study of telisotuzumab vedotin (Teliso-V) + osimertinib (Osi), after failure on prior Osi, in patients with advanced, c-Met overexpressing, EGFR-mutated non-small cell lung cancer (NSCLC)[J]. J Clin Oncol, 2022, 40(16_suppl): 9013.
doi: 10.1200/JCO.2022.40.16_suppl.9013 |
[21] | LI B, SMIT E F, GOTO Y, et al. Primary data from DESTINY-Lung01: a phase 2 trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)[C]. ESMO Congress, 2021. |
[22] |
LI B T, SMIT E F, GOTO Y, et al. Trastuzumab deruxtecan in HER2-mutant non-small cell lung cancer[J]. N Engl J Med, 2022, 386(3): 241-251.
doi: 10.1056/NEJMoa2112431 |
[23] | FDA. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer[EB/OL]. (2022-08-16)[2023-02-02]. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung. |
[24] |
ROMÁN M, BARAIBAR I, LÓPEZ I, et al. KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target[J]. Mol Cancer, 2018, 17(1): 33.
doi: 10.1186/s12943-018-0789-x |
[25] |
RECK M, CARBONE D P, GARASSINO M, et al. Targeting KRAS in non-small cell lung cancer: recent progress and new approaches[J]. Ann Oncol, 2021, 32(9): 1101-1110.
doi: 10.1016/j.annonc.2021.06.001 |
[26] |
JÄNNE P A, RIELY G J, GADGEEL S M, et al. Adagrasib in non-small cell lung cancer harboring a KRAS G12C mutation[J]. N Engl J Med, 2022, 387(2): 120-131.
doi: 10.1056/NEJMoa2204619 |
[27] |
SABARI J K, VELCHETI V, SHIMIZU K, et al. Activity of adagrasib (MRTX849) in brain metastases: preclinical models and clinical data from patients with KRAS G12C-mutant non-small cell lung cancer[J]. Clin Cancer Res, 2022, 28(15): 3318-3328.
doi: 10.1158/1078-0432.CCR-22-0383 |
[28] | FALCHOOK G, LI B T, MARRONE K A, et al. OA03.03 sotorasib in combination with RMC-4630, a SHP2 inhibitor, in KRAS p.G12C-mutated NSCLC and other solid tumors[J]. J Thorac Oncol, 2022, 17(9): S8. |
[29] | ZHOU C, LU Y, KIM S W. Alectinib (ALC) vs crizotinib (CRZ) in Asian patients (pts) with treatment-naïve advanced ALK + non-small cell lung cancer (NSCLC): 5-year update from the phase Ⅲ ALESIA study[J]. Ann Oncol, 2022, 33: S1563. |
[30] |
CAMIDGE D R, DZIADZIUSZKO R, PETERS S, et al. Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced non-small cell lung cancer in the global phase Ⅲ ALEX study[J]. J Thorac Oncol, 2019, 14(7): 1233-1243.
doi: 10.1016/j.jtho.2019.03.007 |
[31] | ZHANG L, FANG W, MIN J, et al. Envonalkib vs crizotinib in treatment-naïve advanced ALK-positive NSCLC: a randomized, multicenter, phase Ⅲ trial[J]. Ann Oncol, 2022, 33: S1564-S1565. |
[32] | LEE S M, SCHULZ C, PRABHASH K, et al. IPSOS: Results from a phase Ⅲ study of first-line (1L) atezolizumab (atezo) vs single-agent chemotherapy (chemo) in patients (pts) with NSCLC not eligible for a platinum-containing regimen[J]. Ann Oncol, 2022, 33: S1418-S1419. |
[33] | GARASSINO M C, GADGEEL S M, SPERANZA G, et al. KEYNOTE-189 5-year update: first-line pembrolizumab (pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC[J]. Ann Oncol, 2022, 33: S992-S993. |
[34] | NOVELLO S, KOWALSKI D M, LUFT A, et al. Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer: 5-year update of the phase Ⅲ KEYNOTE-407 study[J]. J Clin Oncol, 2023. [Online ahead of print] |
[35] | JOHNSON M, CHO B C, LUFT A, et al. Durvalumab (D)±tremelimumab (T) + chemotherapy (CT) in 1L metastatic (m) NSCLC: overall survival (OS) update from POSEIDON after median follow-up (mFU) of approximately 4 years (y)[J]. Ann Oncol, 2022, 33: S1424-S1425. |
[36] |
RECKAMP K L, REDMAN M W, DRAGNEV K H, et al. Phase Ⅱ randomized study of ramucirumab and pembrolizumab versus standard of care in advanced non-small cell lung cancer previously treated with immunotherapy-lung-MAP S1800A[J]. J Clin Oncol, 2022, 40(21): 2295-2306.
doi: 10.1200/JCO.22.00912 |
[37] |
PROF, SHUN, LU, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial[J]. Lancet Oncol, 2022, 23(9): 1167-1179.
doi: 10.1016/S1470-2045(22)00382-5 |
[38] | LEVY B, PAZ-ARES L, RIXE O, et al. MA13.07 TROPION-Lung02: initial results for datopotamab deruxtecan plus pembrolizumab and platinum chemotherapy in advanced NSCLC[J]. J Thorac Oncol, 2022, 17(9): S91. |
[39] |
RECKAMP K L, REDMAN M W, DRAGNEV K H, et al. Overall survival from a phase Ⅱ randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with immunotherapy: lung-MAP nonmatched substudy S1800A[J]. J Clin Oncol, 2022, 40(suppl 16): 9004.
doi: 10.1200/JCO.2022.40.16_suppl.9004 |
[1] | TIAN Xi, XU Wenhao, ZHU Shuxuan, AIHETAIMUJIANG•Anwaier, SU Jiaqi, YE Shiqi, QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei. Advances in the research, diagnosis and treatment of renal cell carcinoma in 2022 [J]. China Oncology, 2023, 33(3): 191-200. |
[2] | CAO Xiaoshan, CONG Binbin. The research progress of endocrine therapy combined with targeted therapy for triple-positive breast cancer [J]. China Oncology, 2023, 33(3): 288-292. |
[3] | SHAO Zhibo, YANG Benlong, WU Jiong. Progress of important clinical trials of breast cancer in China in 2022 [J]. China Oncology, 2023, 33(2): 103-109. |
[4] | CHEN Yingyao, CHU Xiangling, YU Xin, SU Chunxia. Advances in models predicting efficacy of immune checkpoint inhibitors [J]. China Oncology, 2023, 33(1): 61-70. |
[5] | XIAO Yuling, ZHU Xiuzhi, JIANG Yizhou, SHAO Zhimin. New research advances and future prospect in precision treatment of triple-negative breast cancer [J]. China Oncology, 2022, 32(8): 669-679. |
[6] | ZHOU Wenbin, XIE Hui, DING Qiang, WANG Shui. New research progress of microwave ablation in the local precise treatment of early-stage breast cancer: the prospect of combined immunotherapy is promising [J]. China Oncology, 2022, 32(8): 698-704. |
[7] | HE Liyuan, WANG Yudong. Research progress of ALK kinase domain drug resistance mutation and its future countermeasures [J]. China Oncology, 2022, 32(8): 736-746. |
[8] | HONG Yaping, HUANG Yunjian, HUANG Zhangzhou, CHEN Shengjia, ZHONG Qiaofeng, ZENG Hongfu, ZHUANG Wu. Efficacy and prognostic predictors of first-generation EGFR TKI-targeted therapy in patients with EGFR-mutated advanced non-small cell lung cancer [J]. China Oncology, 2022, 32(7): 624-634. |
[9] | SU Chunxia, ZHOU Caicun. Current status and future directions of immunotherapy for advanced non-small cell lung cancer [J]. China Oncology, 2022, 32(6): 478-486. |
[10] | YU Silai, NI Jianjiao, ZHU Zhengfei. Treatment of unresectable locally advanced non-small cell lung cancer in the era of immunotherapy: status and prospects [J]. China Oncology, 2022, 32(6): 487-498. |
[11] | LI Xiaoqiu, CD30 Positive Lymphoma Pathology Expert Group. Detection of CD30 expression in lymphomas: status and challenges [J]. China Oncology, 2022, 32(6): 512-518. |
[12] | SU Jiaqi, XU Wenhao, TIAN Xi, ANWAIE Aihetaimujiang, QU Yuanyuan, SHI Guohai, ZHANG Hailiang, YE Dingwei. New strategies for combined with immunotherapy of clear cell renal cell carcinoma: advances in aerobic glycolysis [J]. China Oncology, 2022, 32(4): 287-297. |
[13] | FU Yuanyuan, HOU Runping, FU Xiaolong. Research progress in predicting the risk of lymphatic or hematologic metastasis based on chest CT in early non-small cell lung cancer [J]. China Oncology, 2022, 32(4): 343-350. |
[14] | CHEN Guangliang, WU Fangtian, CAO Junning. Advances in research on EBV positive diffuse large B-cell lymphoma, not otherwise specified [J]. China Oncology, 2022, 32(3): 258-267. |
[15] | LI Yujie, CHEN Hao. Potential of targeting TROP2 in the treatment of pancreatic cancer [J]. China Oncology, 2022, 32(3): 268-273. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd